BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34318651)

  • 21. ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.
    Heidegger I; Klocker H; Pichler R; Pircher A; Prokop W; Steiner E; Ladurner C; Comploj E; Lunacek A; Djordjevic D; Pycha A; Plas E; Horninger W; Bektic J
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):271-275. PubMed ID: 28322234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
    Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
    Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.
    Loeb S; Sokoll LJ; Broyles DL; Bangma CH; van Schaik RH; Klee GG; Wei JT; Sanda MG; Partin AW; Slawin KM; Marks LS; Mizrahi IA; Shin SS; Cruz AB; Chan DW; Roberts WL; Catalona WJ
    J Urol; 2013 May; 189(5):1702-6. PubMed ID: 23206426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
    Abrate A; Lughezzani G; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Buffi N; Guazzoni G; Lazzeri M
    Korean J Urol; 2014 Jul; 55(7):436-45. PubMed ID: 25045441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate Health Index density improves detection of clinically significant prostate cancer.
    Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
    BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
    Tosoian JJ; Loeb S; Feng Z; Isharwal S; Landis P; Elliot DJ; Veltri R; Epstein JI; Partin AW; Carter HB; Trock B; Sokoll LJ
    J Urol; 2012 Oct; 188(4):1131-6. PubMed ID: 22901577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
    Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
    Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
    Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
    Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
    Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
    Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
    BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
    Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
    Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study.
    Lazzeri M; Lughezzani G; Haese A; McNicholas T; de la Taille A; Buffi NM; Cardone P; Hurle R; Casale P; Bini V; Redorta JP; Graefen M; Guazzoni G
    Urol Oncol; 2016 Sep; 34(9):415.e13-9. PubMed ID: 27178729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
    Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
    Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
    Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
    Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.
    Hori S; Blanchet JS; McLoughlin J
    BJU Int; 2013 Oct; 112(6):717-28. PubMed ID: 22759214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
    Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
    Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.
    Makarov DV; Isharwal S; Sokoll LJ; Landis P; Marlow C; Epstein JI; Partin AW; Carter HB; Veltri RW
    Clin Cancer Res; 2009 Dec; 15(23):7316-21. PubMed ID: 19934305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of
    Nandakumar V; Bornhorst JA; Algeciras-Schimnich A
    Ann Clin Lab Sci; 2021 Jan; 51(1):3-11. PubMed ID: 33653775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
    Jagarlamudi KK; Zupan M; Kumer K; Fabjan T; Hlebič G; Eriksson S; Osredkar J; Smrkolj T
    Prostate; 2019 Jun; 79(8):856-863. PubMed ID: 30889628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.